Company: ABBV
Filing Date: 2025-03-10
Form Type: PRE 14A
Source: 0001558370-25-002603
Chunk: 28

Company: AbbVie Inc.
Filing Date: 2025-03-10
Form: PRE 14A
Chunk 28
---
 500 Index and the NYSE Arca Pharmaceutical Index. The following graph covers the period from December 31, 2014 through December 31, 2024. This graph assumes $100 was invested in AbbVie common stock and each index on December 31, 2014 and also assumes the reinvestment of dividends. The stock price performance in the following graph is not necessarily indicative of future stock price performance. Comparison of Cumulative Total Stockholder Return – Last Ten Years STOCKHOLDER ENGAGEMENT 2024 Say on Pay Results

| ​                                                                                                                                                                                                                                                 | ​ | ​ | ​                  |
| At our 2024 Annual Meeting, the say on pay proposal received support from 91.8% of our stockholders. The Board and compensation committee are encouraged by the continued, consistent stockholder support for our executive compensation program. |   |   | 91.8%              
 Say on Pay Results |
| ​                                                                                                                                                                                                                                                 | ​ | ​ | ​                  |

AbbVie is committed to regular, ongoing engagement with stockholders to ensure that we continue to understand stockholder feedback about our compensation program and incorporate that feedback into the compensation decision-making process. To that end, in 2024 AbbVie reached out to stockholders representing over 45% of the company’s outstanding shares. In these discussions, the aggregate feedback acknowledged the alignment of our executives’ pay with AbbVie’s performance and expressed support for our compensation program, consistent with the level of stockholder support for our say on pay proposals since inception. The feedback informs the compensation committee’s continuous assessment of the program design and ongoing discussions with stockholders, which contribute to the evolution of the programs.

2025 Proxy Statement |37

| ​                      | ​ |
| EXECUTIVE COMPENSATION | ​ |

COMPENSATION PROGRAM GOVERNANCE SUMMARY In addition to strong alignment of pay with the performance of the company and our NEOs, we maintain and are committed to good governance practices, including the following:

| ​ |                                               | ●●●​                                                                                                                                                                                              |
| ​ | Good Governance Practices                     |                                                                                                                                                                                                   |
| ​ | Balanced Incentive Plan Design                | ✓Annual incentive plan includes financial, operational, and strategic metrics to assess performance                                                                                               
 ✓Annual incentive payout matrix used to define and cap the range for the committee’s determinations (at or below the plan maximum of 200% of target with a 2024 payout matrix cap of 190%)        
 ✓Long-term incentive design emphasizing multiple, relative performance metrics and multi